Webinar: Cell Therapies for Parkinson’s Disease from Discovery to Clinic

Return to CIRM Meetings and Events


CIRM / Regenerative Medicine Consortium (RMC)

Cell Therapies for Parkinson’s Disease from Discovery to Clinic

Presentations from FDA and Leading Experts

A Webinar was held on November 14th, 2013


Webinar Presentation Links



  • Ellen Feigal, MD, Senior Vice President of Research and Development, CIRM

Expert Speakers:

  • Wilson Bryan, M.D., Director, Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT), Office of Cellular, Tissue and Gene Therapies (OCTGT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
  • Jeffrey Kordower, Ph.D., Professor of Neurological Sciences and Neurology, Rush University Medical Center
  • Sheryl Osborne, Consultant in Regulatory Affairs and Clinical Development

Topics that were covered:

The focus of this webinar was on Parkinson’s Disease – using the Lessons Learned to overcome the challenges as cell based therapies move from discovery to the clinic.

  • Presentation by FDA – Considerations for first-in-human clinical trials of cell therapies for Parkinson’s Disease
  • Lessons learned from human fetal transplants and from gene therapy
  • State of preclinical research with hESCs and hiPSC cell therapies
  • Questions and Answers







Date Published: October 18, 2013
Last Modified: June 28, 2022